Literature DB >> 7784479

Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.

W Linz1, G Wiemer, P Gohlke, T Unger, B A Schölkens.   

Abstract

From pharmacological investigations and clinical studies, it is known that ACE inhibitors exhibit additional local actions that are not related to hemodynamic changes and that cannot be explained only by interference with the renin-angiotensin system by means of an inhibition of ANG II formation. Because ACE is identical to kininase II, which inactivates the nonapeptide BK and related kinins, potentiation of kinins might be responsible for these additional effects of ACE inhibitors. ACE inhibition, concentration, and time dependently increased the formation of NO and PGI2 in cultured endothelial cells of different origin and from different species, including humans. The specific B2 kinin receptor antagonist, icatibant, suppressed the ACE inhibitor-induced increase in endothelial cyclic GMP accumulation index for NO-formation and, in parallel, attenuated the increase in PGI2 release. In renovascular models of hypertension associated with a stimulated renin-angiotensin system (two-kidney, one-clip), blood pressure reduction by ACE inhibitors was attenuated by icatibant, whereas in rats with genetic hypertension with normal to low plasma renin, blood pressure reduction through ACE inhibitors was not affected. In experimental atherosclerosis in rabbits, ACE inhibitors were able to preserve endothelial function and vascular reactivity and to reduce surface involvement. In the balloon denudation model of carotid arteries in rats, it was found that ACE inhibition markedly reduced neointima formation. However, when the ACE inhibitor was given together with icatibant, its effect was significantly blunted. Perfusion with ACE inhibitors induced a reduction of the incidence, as well as of the duration, of ventricular fibrillation and improved cardiodynamics and myocardial metabolism. BK perfusion induced comparable cardioprotective effects. In addition, perfusion with ACE inhibitors markedly increased the outflow of BK and related kinins from isolated rat hearts. The antiischemic effect of ACE inhibitors and BK were abolished by the addition of L-NNA (1 x 10(-6) mol/l) or icatibant (1 x 10(-9) mol/l). Similar results were found in dogs and rabbits with myocardial infarction. BK and related kinins also seem to be involved in preconditioning and remodeling. The effect of ACE inhibition in LVH was investigated in rats made hypertensive by aortic banding. ACE inhibition with ramipril, in the antihypertensive dose of 1 mg/kg/day for 6 weeks, prevented the increase in blood pressure and the development of LVH. A lower, nonantihypertensive dose of the ACE inhibitor (10 micrograms/kg/day for 6 weeks) had no effect on the increase in blood pressure or on plasma ACE activity, but also prevented LVH after aortic banding.4+ off

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7784479

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  74 in total

1.  Intracellular Angiotensin II and cell growth of vascular smooth muscle cells.

Authors:  C M Filipeanu; R H Henning; D de Zeeuw; A Nelemans
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

2.  Toward a new anti-inflammatory and analgesic agent.

Authors:  D Regoli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 3.  Omapatrilat: a new tool for understanding metabolism of bradykinin at the endothelium level.

Authors:  M J Dumoulin; D Lamontagne; G Molinaro; A Adam
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 4.  Age-related endothelial dysfunction : potential implications for pharmacotherapy.

Authors:  Rachel L Matz; Ramaroson Andriantsitohaina
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 5.  Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications.

Authors:  Seema A Kothari; Mytrang K Le; Pritesh J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

6.  Inhibition of kinin breakdown prolongs retention and action of bradykinin in a myocardial B2 receptor compartment.

Authors:  Andreas Dendorfer; Verena Folkers; Matthias Klinger; Sebastian Wolfrum; Peter Dominiak
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

7.  Role of the angiotensin II receptor blocker valsartan in heart failure.

Authors:  R L Webb; M de Gasparo
Journal:  Exp Clin Cardiol       Date:  2001

8.  Stimulation of phosphatidylinositol hydrolysis, protein kinase C translocation, and mitogen-activated protein kinase activity by bradykinin in rat ventricular myocytes: dissociation from the hypertrophic response.

Authors:  A Clerk; J Gillespie-Brown; S J Fuller; P H Sugden
Journal:  Biochem J       Date:  1996-07-01       Impact factor: 3.857

9.  Bradykinin antagonist counteracts the acute effect of both angiotensin-converting enzyme inhibition and of angiotensin receptor blockade on the lower limit of autoregulation of cerebral blood flow.

Authors:  Sigurdur T Sigurdsson; Olaf B Paulson; Arne Høj Nielsen; Svend Strandgaard
Journal:  J Cereb Blood Flow Metab       Date:  2013-12-11       Impact factor: 6.200

10.  Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insufficiency induced by chronic NO-synthase inhibition in rats.

Authors:  M Hropot; K H Langer; Gabriele Wiemer; H Grötsch; W Linz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-25       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.